CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 92 filers reported holding CONCERT PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $6,355,649 | -12.8% | 1,088,296 | 0.0% | 0.13% | -17.3% |
| Q3 2022 | $7,292,000 | -47.6% | 1,088,296 | -67.1% | 0.16% | -58.0% |
| Q2 2022 | $13,923,000 | +36.2% | 3,307,203 | +9.0% | 0.37% | +66.4% |
| Q1 2022 | $10,223,000 | +7.0% | 3,033,603 | 0.0% | 0.22% | +32.7% |
| Q4 2021 | $9,556,000 | -3.7% | 3,033,603 | 0.0% | 0.17% | +22.6% |
| Q3 2021 | $9,920,000 | -22.5% | 3,033,603 | 0.0% | 0.14% | -33.2% |
| Q2 2021 | $12,802,000 | -15.4% | 3,033,603 | 0.0% | 0.20% | -10.1% |
| Q1 2021 | $15,138,000 | -34.3% | 3,033,603 | +66.4% | 0.23% | -29.2% |
| Q4 2020 | $23,049,000 | +26.3% | 1,823,520 | -1.9% | 0.32% | -3.6% |
| Q3 2020 | $18,250,000 | -1.3% | 1,858,474 | 0.0% | 0.33% | -7.2% |
| Q2 2020 | $18,492,000 | +12.6% | 1,858,474 | 0.0% | 0.36% | -30.6% |
| Q1 2020 | $16,429,000 | +65.1% | 1,858,474 | +178.0% | 0.52% | -48.2% |
| Q2 2015 | $9,953,000 | -0.4% | 668,406 | +1.3% | 1.00% | +0.8% |
| Q1 2015 | $9,996,000 | – | 660,000 | – | 0.99% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| L1 Capital Pty Ltd | 1,149,120 | $14,559,000 | 2.72% |
| Corriente Advisors, LLC | 680,000 | $8,595,000 | 2.05% |
| ACUTA CAPITAL PARTNERS, LLC | 537,500 | $6,794,000 | 1.85% |
| INGALLS & SNYDER LLC | 1,362,203 | $17,218,000 | 0.85% |
| Kensington Investment Counsel, LLC | 75,533 | $955,000 | 0.79% |
| SPHERA FUNDS MANAGEMENT LTD. | 384,039 | $4,854,000 | 0.43% |
| Opaleye Management Inc. | 254,000 | $3,211,000 | 0.42% |
| RA Capital Management | 1,823,520 | $23,049,000 | 0.32% |
| Perceptive Advisors | 2,150,641 | $27,184,000 | 0.29% |
| Parkman Healthcare Partners LLC | 50,290 | $636,000 | 0.16% |